Production, Radiochemical Separation and Radiolabeling of Gold Nanoparticle Bioconjugates with 211At for Targeted Alpha Therapy

被引：0
|
作者：
Ghosh, S. [1 ,2 ]
Banerjee, D. [1 ,3 ]
Chakravarty, R. [1 ,2 ]
机构：
[1] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India
[2] Bhabha Atom Res Ctr, Radiopharmaceut Div, Mumbai, Maharashtra, India
[3] BARC, Variable Energy Cyclotron Ctr, Radiochem Div, Kolkata, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-280
引用
收藏
页码：S130 / S131
页数：2
相关论文
共 50 条
  • [21] Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
    Ukon, Naoyuki
    Higashi, Tatsuya
    Hosono, Makoto
    Kinuya, Seigo
    Yamada, Takahiro
    Yanagida, Sachiko
    Namba, Masao
    Nakamura, Yoshihide
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (08) : 695 - 709
  • [22] Manual on the proper use of meta-[211At] astato-benzylguanidine ([211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
    Naoyuki Ukon
    Tatsuya Higashi
    Makoto Hosono
    Seigo Kinuya
    Takahiro Yamada
    Sachiko Yanagida
    Masao Namba
    Yoshihide Nakamura
    Annals of Nuclear Medicine, 2022, 36 : 695 - 709
  • [23] Evaluation of new targeted alpha therapy using astatine (211At) labeled PSMA5 for prostate cancer
    Watabe, Tadashi
    Toyoshima, Atsushi
    Fukase, Koichi
    CANCER SCIENCE, 2023, 114 : 119 - 119
  • [24] Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs
    Wang, Xudong
    Ma, Wenzong
    Liu, Weihao
    Ma, Huan
    Yang, Yuanyou
    Wang, Yugang
    Liu, Ning
    Yang, Gen
    JOURNAL OF RADIATION RESEARCH, 2020, 61 (05) : 684 - 690
  • [25] Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [211At] NaAt in Mice: A Revisit
    Liu, Yuwei
    Watabe, Tadashi
    Kaneda-Nakashima, Kazuko
    Ooe, Kazuhiro
    Shirakami, Yoshifumi
    Toyoshima, Atsushi
    Shimosegawa, Eku
    Nakano, Takashi
    Shinohara, Atsushi
    Hatazawa, Jun
    TRANSLATIONAL ONCOLOGY, 2020, 13 (04):
  • [26] Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [211At] NaAt in mice: a revisit
    Yuwei, Liu
    Watabe, Tadashi
    Kaneda-Nakashima, Kazuko
    Ooe, Kazuhiro
    Shirakami, Yoshifumi
    Toyoshima, Atsushi
    Shimosegawa, Eku
    Nakano, Takashi
    Shinohara, Atsushi
    Hatazawa, Jun
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [27] Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy
    Leidermark, Erik
    Hallqvist, Andreas
    Jacobsson, Lars
    Karlsson, Per
    Holmberg, Erik
    Back, Tom
    Johansson, Mia
    Lindegren, Sture
    Palm, Stig
    Albertsson, Per
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 165 - 172
  • [28] Estimated absorbed dose in human after intravenous administration of [211At]NaAt for the FIH clinical trial of targeted alpha therapy
    Watabe, T.
    Sato, T.
    Kaneda, K.
    Ooe, K.
    Liu, Y.
    Kurimoto, K.
    Toyoshima, A.
    Shinohara, A.
    Shirakami, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S41 - S42
  • [29] Targeted alpha therapies using 211At: A Geant4 simulation of dose and DNA damage
    De Sio, Chiara
    Ballisat, Laura
    Beck, Lana
    Guatelli, Susanna
    Sakata, Dousatsu
    Shi, Yuyao
    Duan, Jinyan
    Abu Sabah, Lujin
    Velthuis, Jaap
    Rosenfeld, Anatoly
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2025, 129
  • [30] Targeted alpha therapy using [211At]PSMA5 against refractory prostate cancer: preclinical studies for the clinical trial
    Watabe, Tadashi
    Kaneda, Kazuko
    Toyoshima, Atsushi
    Fukase, Koichi
    CANCER SCIENCE, 2024, 115 : 1561 - 1561
12345